Aston Martin Lagonda Global Holdings Plc has some additional excitement to accompany its recent podium finishes at Formula

Using existing drugs to treat cervical cancer before standard treatment could lead to a 35% reduction in the risk of relapse or death, a new study suggests. Researchers from the UCL Cancer Institute and UCLH looked into whether a short course of induction chemotherapy (IC), where a drug is used to destroy as many cancer cells as possible, before chemoradiation (CRT), could help with this. Here’s everything you need to know about the findings… What is cervical cancer? According to the NHS website, cervical cancer is a type of cancer found anywhere near the cervix – the opening between the vagina and the womb (uterus), which is also known as the neck of the womb. Most cervical cancers grow very slowly and are caused by an infection from specific types of human papillomavirus (HPV) and mostly affect women under the age of 45. According to Jo’s Cervical Cancer Trust, symptoms include vaginal bleeding that is unusual to you, changes to vaginal discharge, discomfort during sex and pain in your lower back or pelvis. Changes to cells can be spotted by a cervical screening, and then treated before they turn into cancer. There are around 3,200 new cases every year in the UK, with the five-year survival rate being around 70%, according to Cancer Research UK. CRT has been the standard treatment for cervical cancer patients since 1999, but even though there have been overall significant developments in radiation therapy techniques, up to 30% of people experience their cancer coming back. What did the research involve? Over a 10-year period, 500 patients who had been diagnosed with cervical cancer – that was large enough to see without a microscope but hadn’t spread to other parts of the body – took part in the Interlace trial at hospitals in the UK, Mexico, India, Italy and Brazil. Researchers looked into whether a short course of IC before CRT could reduce rates of relapse and death. What results were found? After five years, researchers discovered that 80% of the people who received a combination of chemotherapy and radiotherapy were alive, whilst 73% had not seen their cancer return or spread. A major benefit, according to researchers, is that it can be incorporated into standard of care treatment relatively quickly, because cheap, accessible and already-approved ingredients such as carboplatin and paclitaxel are needed for IC. “Our trial shows that this short course of additional chemotherapy delivered immediately before the standard CRT can reduce the risk of the cancer returning or death by 35%,” said Dr Mary McCormack, lead investigator of the trial from UCL Cancer Institute and UCLH. “This is the biggest improvement in outcome in this disease in over 20 years. “I’m incredibly proud of all the patients who participated in the trial; their contribution has allowed us to gather the evidence needed to improve treatment of cervical cancer patients everywhere. “We couldn’t have done this without the generous support of Cancer Research UK.” Why is the research important? Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: “Timing is everything when you’re treating cancer. The simple act of adding induction chemotherapy to the start of chemoradiation treatment for cervical cancer has delivered remarkable results in this trial. “A growing body of evidence is showing the value of additional rounds of chemotherapy before other treatments like surgery and radiotherapy in several other cancers. “Not only can it reduce the chances of cancer coming back, it can be delivered quickly using drugs already available worldwide. “We’re excited for the improvements this trial could bring to cervical cancer treatment and hope short courses of induction chemotherapy will be rapidly adopted in the clinic.”

(Reuters) -Under Armour beat market expectations for first-quarter revenue on Tuesday, as discounts upheld demand for the sportswear maker's clothes

TL;DR: The international friendly match between England and Australia will take place at 7:45 p.m.

GREENSBORO, N.C.--(BUSINESS WIRE)--May 24, 2023--

The leader of the United Nations has urged Russia to resume the internationally-brokered deal so that grain can be shipped from Ukraine's Black Sea ports during the war

Dixie D'Amelio is well-known for making a statement with her fashion choices or her social media videos

Love it or hate it, Intel is overhauling its system of naming and marketing its

Eurostar passengers departing from London can avoid one of two manual passport checks through a facial verification system. The launch of the technology at St Pancras station – which also removes the need to scan tickets – is aimed at easing congestion. To participate, passengers must use an app before travel to scan their identity document and verify their face and ticket. At the station they walk in front of a screen and have their face detected. If they are approved they can proceed through doors which open automatically. The SmartCheck system, developed by iProov, is available to Business Premier and Carte Blanche passengers. Users no longer need to have their passports scanned by Eurostar’s UK contractors carrying out exit checks. Bags are still being scanned by security staff and French border officials are continuing to check passports. It emerged earlier this year that Eurostar was being forced to leave hundreds of seats empty on trains to and from London to avoid long queues at stations. The situation has since improved but dozens of seats are not being offered for sale on some services. Enhanced post-Brexit checks carried out by French border officials have significantly increased the time it takes to process passengers at the station. Eurostar chief executive Gwendoline Cazenave said: “Providing a seamless station experience to our customers is a priority for Eurostar. “We continue looking for solutions to increase capacity in stations and simplify the passengers’ flows. “SmartCheck in St Pancras International station is a solution for a faster and seamless check-in experience. “By introducing SmartCheck, we become the first rail travel operator to adopt biometric face verification. “This innovation will enhance our customer departure journey, which is crucial to provide Eurostar’s unique travel experience.” Andrew Bud, chief executive of iProov, said: “The rollout of SmartCheck in Eurostar’s Business Premier check-in at London St Pancras is significant because it clearly demonstrates how facial biometric technology can be used to manage border control in a smarter and more efficient way, to benefit both organisations and passengers at scale. “By creating a biometric corridor, we are moving security checks away from the station, saving precious time and space at the border, streamlining the boarding process to one that’s far faster, more convenient, less crowded and stressful, yet even more secure.” Heathrow Airport began trialling facial biometric scanners in 2019 but the project was dropped when passenger numbers collapsed due to the coronavirus pandemic. Read More Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live ‘Hostile states using organised crime gangs as proxies in the UK’ Kim Kardashian, Rylan Clark and Dalai Lama among those joining new app Threads Mastercard helping banks predict scams before money leaves customers’ accounts

Peloton is recalling more than 2 million of its exercise bikes because the bike’s seat post assembly can break during use, posing fall and injury hazards

The WHO said Friday it was now classifying aspartame, an artificial sweetener commonly used in soft drinks, as "possibly carcinogenic to humans" -- though the...

Maybe it’s a boarding pass for an upcoming holiday flight. Maybe it’s making your own